Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 576

1.

Validation of the Brief Fear of Negative Evaluation Scale-II in patients with systemic sclerosis: A Scleroderma Patient-centered Intervention Network Cohort study.

Fox RS, Kwakkenbos L, Carrier ME, Mills SD, Gholizadeh S, Jewett LR, Roesch SC, Merz EL, Assassi S, Furst DE, Gottesman K, Mayes MD, Thombs BD, Malcarne VL; SPIN Investigators.

Arthritis Care Res (Hoboken). 2018 Feb 6. doi: 10.1002/acr.23532. [Epub ahead of print]

PMID:
29409146
2.

Secular trends in the impact factors of SLE publications over a 45-year period-a systematic review.

Cohen N, Mimouni M, Glatstein MM, Furst DE, Amarilyo G.

Lupus. 2018 Jan 1:961203317751855. doi: 10.1177/0961203317751855. [Epub ahead of print]

PMID:
29320973
3.

Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.

Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, Mayes MD, Nash RA, Crofford LJ, Eggleston B, Castina S, Griffith LM, Goldstein JS, Wallace D, Craciunescu O, Khanna D, Folz RJ, Goldin J, St Clair EW, Seibold JR, Phillips K, Mineishi S, Simms RW, Ballen K, Wener MH, Georges GE, Heimfeld S, Hosing C, Forman S, Kafaja S, Silver RM, Griffing L, Storek J, LeClercq S, Brasington R, Csuka ME, Bredeson C, Keever-Taylor C, Domsic RT, Kahaleh MB, Medsger T, Furst DE; SCOT Study Investigators.

N Engl J Med. 2018 Jan 4;378(1):35-47.

PMID:
29298160
4.

Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations.

Gorlova OY, Li Y, Gorlov I, Ying J, Chen WV, Assassi S, Reveille JD, Arnett FC, Zhou X, Bossini-Castillo L, Lopez-Isac E, Acosta-Herrera M, Gregersen PK, Lee AT, Steen VD, Fessler BJ, Khanna D, Schiopu E, Silver RM, Molitor JA, Furst DE, Kafaja S, Simms RW, Lafyatis RA, Carreira P, Simeon CP, Castellvi I, Beltran E, Ortego N, Amos CI, Martin J, Mayes MD.

PLoS One. 2018 Jan 2;13(1):e0189498. doi: 10.1371/journal.pone.0189498. eCollection 2018.

5.

Scleroderma renal crisis and renal involvement in systemic sclerosis.

Woodworth TG, Suliman YA, Li W, Furst DE, Clements P.

Nat Rev Nephrol. 2018 Feb;14(2):137. doi: 10.1038/nrneph.2017.183. Epub 2018 Jan 2.

PMID:
29292373
6.

A Case Series on Patients on Tofacitinib in Combination With a Biologic.

Barroso NS, Miller EZ, Furst DE.

J Clin Rheumatol. 2017 Dec 27. doi: 10.1097/RHU.0000000000000663. [Epub ahead of print] No abstract available.

PMID:
29280829
7.

Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs.

Rigby WFC, Lampl K, Low JM, Furst DE.

Int J Rheumatol. 2017;2017:9614241. doi: 10.1155/2017/9614241. Epub 2017 Oct 31. Review.

8.

Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).

Kafaja S, Clements PJ, Wilhalme H, Tseng CH, Furst DE, Kim GH, Goldin J, Volkmann ER, Roth MD, Tashkin DP, Khanna D.

Am J Respir Crit Care Med. 2017 Nov 3. doi: 10.1164/rccm.201709-1845OC. [Epub ahead of print]

PMID:
29099620
9.

Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study.

Hsu VM, Denton CP, Domsic RT, Furst DE, Rischmueller M, Stanislav M, Steen VD, Distler JHW, Korish S, Cooper A, Choi S, Schafer PH, Horan G, Hough DR.

J Rheumatol. 2017 Nov 1. pii: jrheum.161040. doi: 10.3899/jrheum.161040. [Epub ahead of print]

PMID:
29093152
10.

Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis.

Arnold MB, Khanna D, Denton CP, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Riemekasten G, Steen V, Müller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE, Pope JE.

Rheumatology (Oxford). 2018 Jan 1;57(1):152-157. doi: 10.1093/rheumatology/kex396.

PMID:
29077900
11.

Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).

Khanna D, Denton CP, Lin CJF, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, Müller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE.

Ann Rheum Dis. 2018 Feb;77(2):212-220. doi: 10.1136/annrheumdis-2017-211682. Epub 2017 Oct 24.

12.

Interstitial lung disease points to consider for clinical trials in systemic sclerosis.

Khanna D, Seibold J, Goldin J, Tashkin DP, Furst DE, Wells A.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v27-v32. doi: 10.1093/rheumatology/kex203. Review.

PMID:
28992174
13.

Assessment of skin involvement in systemic sclerosis.

Kumánovics G, Péntek M, Bae S, Opris D, Khanna D, Furst DE, Czirják L.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v53-v66. doi: 10.1093/rheumatology/kex202. Review.

PMID:
28992173
14.

Points to consider in renal involvement in systemic sclerosis.

Galluccio F, Müller-Ladner U, Furst DE, Khanna D, Matucci-Cerinic M.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v49-v52. doi: 10.1093/rheumatology/kex201. Review.

PMID:
28992172
15.

Points to consider for skin ulcers in systemic sclerosis.

Galluccio F, Allanore Y, Czirjak L, Furst DE, Khanna D, Matucci-Cerinic M.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v67-v71. doi: 10.1093/rheumatology/kex200. Review.

PMID:
28992171
16.

Points to consider-Raynaud's phenomenon in systemic sclerosis.

Cutolo M, Smith V, Furst DE, Khanna D, Herrick AL.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v45-v48. doi: 10.1093/rheumatology/kex199. Review.

PMID:
28992170
17.

Points to consider when doing a trial primarily involving the heart.

Allanore Y, Distler O, Walker UA, Khanna D, Furst DE, Meune C.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v12-v16. doi: 10.1093/rheumatology/kex198. Review.

PMID:
28992169
18.

Pulmonary hypertension related to systemic sclerosis: points to consider for clinical trials.

Humbert M, Singh M, Furst DE, Khanna D, Seibold JR.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v33-v37. doi: 10.1093/rheumatology/kex197. Review.

PMID:
28992168
19.

Muscle involvement in systemic sclerosis: points to consider in clinical trials.

Walker UA, Clements PJ, Allanore Y, Distler O, Oddis CV, Khanna D, Furst DE.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v38-v44. doi: 10.1093/rheumatology/kex196. Review.

PMID:
28992167
20.

Points to consider for clinical trials of the gastrointestinal tract in systemic sclerosis.

Furst DE, Braun-Moscovic Y, Khanna D.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v4-v11. doi: 10.1093/rheumatology/kex195. Review.

PMID:
28992166

Supplemental Content

Loading ...
Support Center